HC tells Tukaram-led FDA to use power judiciously
The Bombay High Court has urged the Maharashtra Food and Drug Administration (FDA) to exercise its powers with care following a dispute between Cadila Pharmaceuticals Ltd and the regulator. The court expressed concern over the FDA's decision to halt the sale of certain Cadila medicines, questioning the approach taken by the regulatory body.
The FDA assured the court that it would revoke the orders against Cadila, followed by show-cause notices and a hearing, according to a TOI report. Cadila's senior advocate, Birendra Saraf, argued that the dispute involved the broader issue of brand extensions in the pharmaceutical industry, and that the Ministry of Health had initiated a public consultation on July 6, 2026, on the matter.
The FDA offered to withdraw its orders, issue show-cause notices and allow Cadila an opportunity to be heard before passing a reasoned order. The court accepted the FDA's assurance and dismissed Cadila's plea, instructing the regulator to "be judicious" in its actions.
Written by urgent.news from The Economic Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
